14.30 - 16.00

ACROSS T2D symposium

“An endocrinologist, a cardiologist and a nephrologist walk into a bar...” Cross-specialty debates in diabetes

Silvio Inzucchi and Sarah Jarvis
Welcome and introduction
Francesco Giorgino and Nikolaus Marx
Metformin should remain as ‘foundation therapy’ for the majority of patients with T2D: Yes (Francesco Giorgino) or No (Nikolaus Marx)
Silvio Inzucchi and Francesco Giorgino
The preferred second-line therapy in patients with T2D is: An SGLT2 inhibitor (Silvio Inzucchi) or a GLP-1 RA (Francesco Giorgino)
Nikolaus Marx and Merlin Thomas
In the treatment of patients with T2D, the focus should be on: The heart (Nikolaus Marx) or The kidney (Merlin Thomas)
Sarah Jarvis
The PCP perspective on patient care
Silvio Inzucchi, Francesco Giorgino, Sarah Jarvis, Nikolaus Marx and Merlin Thomas
Panel discussion and Q&A
Silvio Inzucchi
Final remarks and close
Symposium by:
Boehringer Ingelheim & Eli Lilly and Company Alliance